MindWalk Holdings (HYFT) Long-Term Debt Issuances (2024 - 2026)
MindWalk Holdings (HYFT) posted quarterly Long-Term Debt Issuances of -$117450.5 for Q2 2026, down 201.2% quarter-over-quarter from $116061.5 in Q4 2025.
MindWalk Holdings (HYFT) Long-Term Debt Issuances (2024 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Long-Term Debt Issuances for 3 consecutive years, with -$117450.5 the latest figure, recorded in Q2 2026.
- In Q2 2026, Long-Term Debt Issuances changed N/A year-over-year to -$117450.5; the TTM figure through Apr 2026 stood at -$1389.0 (down 100.04% YoY), while the FY2025 annual figure was $3.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances fell to -$117450.5 in Q2 2026 per HYFT's latest filing, from $116061.5 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $1.9 million in Q3 2024 and bottomed at -$117450.5 in Q2 2026.
- Historically, Long-Term Debt Issuances has averaged $618948.7 across 3 years, with a median of $128910.1 in 2025.
- On a YoY basis, Long-Term Debt Issuances climbed as much as 89.14% in 2025 and fell as far as 89.14% in 2025.
- MindWalk Holdings' Long-Term Debt Issuances stood at $1.1 million in 2024, then tumbled by 89.14% to $116061.5 in 2025, then sank by 201.2% to -$117450.5 in 2026.
- Business Quant data shows HYFT's Long-Term Debt Issuances at -$117450.5 in Q2 2026, $116061.5 in Q4 2025, and $128910.1 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -117,450.47 |
| Apr 30, 2026 | -117,450.47 |
| Oct 31, 2025 | 116,061.52 |
| Oct 31, 2025 | 116,061.52 |
| Jan 31, 2025 | 128,910.11 |
| Jan 31, 2025 | 128,910.11 |
| Oct 31, 2024 | 1.07 Mn |
| Oct 31, 2024 | 1.07 Mn |
| Jul 31, 2024 | 1.90 Mn |
| Jul 31, 2024 | 1.90 Mn |